6-乙酰胺基异喹啉 | 566944-05-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 中文名称: 6-乙酰胺基异喹啉
• 英文名称: N-Isoquinolin-6-yl-acetamide
• 英文别名: N-(isoquinolin-6-yl)acetamide；N-isoquinolin-6-ylacetamide
• CAS: 566944-05-6
• 化学式: C₁₁H₁₀N₂O
• 分子量: 186.213
• InChiKey: MEBWHHRSVDGISV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-乙酰胺基异喹啉 在 1-乙酸基-1,2-苯碘酰-3-(1H)-酮 、 bis{rhodium[3,3'-(1,3-phenylene)bis(2,2-dimethylpropanoic acid)]} 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 反应 4.0h， 生成 N-(4-iodo-2-methyl-1-oxo-1,2-dihydroisoquinolin-6-yl)acetamide
  参考文献：
  名称：

  Dirhodium（II）催化的碘代喹啉鎓碘化物盐的1,4-双官能化反应合成4-Iodoisoquinquinolin-1（2 H）-ones

  摘要：

  在温和条件下已开发出有效的Rh 2（II，II）催化反应。该合成方法是通过在好氧条件下容易获得的碘化异喹啉鎓碘化物盐的碘化/氧化来进行的，具有良好或优异的收率。4-碘异喹啉-1（2 H）-1是生物学上和医学上重要的化合物的重要组成部分。所开发的方法应用于革兰氏合成CRTH2拮抗剂CRA-680的关键中间体。

  DOI：

  10.1021/acs.orglett.8b03614
• 作为产物：
  描述：

  6-氨基异喹啉 、 乙酸酐 生成 6-乙酰胺基异喹啉
  参考文献：
  名称：

  Identification of novel and potent isoquinoline aminooxazole-Based IMPDH inhibitors

  摘要：

  Screening of our in-house compound collection led to the discovery of 5-bromo-6-amino-2-isoquinoline I as a weak inhibitor of IMPDH. Subsequent optimization of 1 afforded a series of novel 2-isoquinolinoaminooxazole-based inhibitors, represented by 17, with single-digit nanomolar potency against the enzyme. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00107-0

文献信息

• [EN] FLUORINE- SUBSTITUTED 2 ', 6 ' -DIMETHYL-L-TYROSINE-1, 2,3, 4-TETRAHYDR0IS0QUIN0LINE-3-CARB0XYLIC ACID PEPTIDES (DMT-TIC) FOR USE AS MYU- AND DELTA-OPIOID RECEPTOR PROBES IN<br/>[FR] COMPOSÉS DE DMT-TIC SUBSTITUÉS PAR DU FLUOR ET LEURS PROCÉDÉS D'UTILISATION
  申请人：US HEALTH

  公开号：WO2009032840A1

  公开（公告）日：2009-03-12

  Disclosed are compounds of formula (I) or pharmaceutically acceptable salts thereof: Formula (I) in which R1, R2, and R3 are described herein. Also disclosed is a pharmaceutical composition comprising at least one compound of formula (I) and a pharmaceutically acceptable carrier. Also disclosed is a method of locating a µ- and/or d-opioid receptor that is contained in a tissue or organ.

  揭示了化合物的结构式（I）或其药学上可接受的盐：结构式（I）中R1、R2和R3的描述如本文所述。还揭示了一种包含至少一种结构式（I）化合物和药学上可接受载体的药物组合物。还揭示了一种定位存在于组织或器官中的µ-和/或d-阿片受体的方法。
• 6-Aminoisoquinoline Compounds
  申请人：deLong Mitchell A.

  公开号：US20080167340A1

  公开（公告）日：2008-07-10

  6-Amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.

  提供了影响、抑制或减少激酶作用的6-氨基异喹啉化合物。还提供了包括治疗有效量的6-氨基异喹啉化合物和药用可接受载体的药物组合物。还提供了使用这些化合物和/或组合物来影响疾病状态或疾病条件，如癌症、肥胖和青光眼的各种方法。
• COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT
  申请人：Lee Jung Joon

  公开号：US20090306078A1

  公开（公告）日：2009-12-10

  Disclosed herein are an HIF-1 inhibitor, a method for the preparation thereof, and a pharmaceutical composition comprising the same as an active ingredient. The HIF-1 inhibitor shows anticancer activity thanks to the inhibition activity against HIF-1, a transcription factor which plays an important role in the growth and metastasis of cancer, but not to general cytotoxicity. Thus, the HIF-inhibitor and a pharmaceutically acceptable salt thereof can be used as a therapeutic for various cancers such as liver cancer; stomach cancer and breast cancer. Also, the compound having inhibition activity against HIF-1 is useful in the treatment of diabetic retinopathy and arthritis, which are aggravated by HIF-1-mediated VEGF expression.

  本文披露了一种HIF-1抑制剂，其制备方法，以及包含其作为活性成分的药物组合物。该HIF-1抑制剂显示抗癌活性，这归功于其对HIF-1的抑制活性，HIF-1是一种在癌症生长和转移中起重要作用的转录因子，但不具有一般细胞毒性。因此，HIF抑制剂及其药用可接受的盐可用作治疗各种癌症，如肝癌、胃癌和乳腺癌的治疗药物。此外，具有对HIF-1抑制活性的化合物在治疗由HIF-1介导的VEGF表达加重的糖尿病视网膜病变和关节炎方面是有用的。
• [EN] ION CHANNEL ANTAGONISTS/BLOCKERS AND USES THEREOF<br/>[FR] ANTAGONISTES/BLOQUEURS DES CANAUX IONIQUES ET LEURS UTILISATIONS
  申请人：SHANGHAI EAST HOSPITAL

  公开号：WO2021114313A1

  公开（公告）日：2021-06-17

  Provided are ion channel antagonists/blockers and uses thereof. Specifically, it provides the compounds of formula (I) or pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs, preparation method therefor and application thereof. Definition of each group in the formula can be found in the specification for details. Provided is also pharmaceutical composition useful for treatment of heart disease and other ion channel related diseases.

  提供了离子通道拮抗剂/阻断剂及其用途。具体而言，提供了式（I）的化合物或药用盐、立体异构体、溶剂合物或前药，其制备方法及应用。每个式中的各个基团的定义可在说明书中找到详细信息。还提供了用于治疗心脏病和其他离子通道相关疾病的药物组合物。
• Tricycloundecane compounds useful as modulators of nuclear hormone receptor function
  申请人：Balog Aaron James

  公开号：US20070088029A1

  公开（公告）日：2007-04-19

  Tricycloundecanes compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds are disclosed.

  三环十一烷化合物，以及在治疗核激素受体相关疾病如癌症和免疫紊乱中使用这些化合物的方法，以及含有这些化合物的药物组合物被披露。